^
Association details:
| Biomarker: | EML4-ALK fusion + ALK G1202R |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
Published date:
08/03/2021
Excerpt:
NGS of the patient’s plasma using a panel of 139 cancer-related genes revealed a new ALK G1202R (MAF = 0.2%) mutation, in addition to the EML4-ALK fusion (MAF = 0.1%) (Table 1). A third-line treatment with loratinib was administered at a dose of 100 mg and achieved a PFS of 7 months...
DOI:
https://doi.org/10.2147/OTT.S315832
